Verici Dx receives boost with Thermo Fisher licensing deal
The exclusive license grants Thermo Fisher the rights to develop and offer an assay for pre-transplant risk assessment as a laboratory developed test (LDT) in its CLIA laboratory in the U.S, as well as worldwide rights.
After the deal was announced yesterday, Verici Dx’s shares jumped by 82%, reports Vox Markets.
According to both companies, the aim is to develop a test that can risk stratify patients based on their likely immune response to a transplanted kidney.
As a result, clinicians may be able to make more informed decisions about post-transplant and immunosuppressive management.
Sara Barrington, CEO of Verici Dx, said: “We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most.”
Nicole Brockway, president, transplant diagnostics at Thermo Fisher Scientific, added: “There is a significant need for effective tests that can identify the risk of transplant rejection early to help inform treatment decisions.
"Our hope is that this licensing agreement will allow us to develop a new prognostic assay that will expand and strengthen our portfolio of transplant testing solutions, demonstrating our commitment to enabling clinicians and improving the lives of patients throughout the pre- and post-transplant journey.”
